INT88701

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2000
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 6.04
Pain Relevance 1.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (MMD)
Anatomy Link Frequency
MMA 10
MCA 2
plasma 1
macrophage 1
cortex 1
MMD (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 13 99.20 Very High Very High Very High
IPN 7 98.84 Very High Very High Very High
Migraine 4 97.36 Very High Very High Very High
headache 16 96.84 Very High Very High Very High
cytokine 2 95.40 Very High Very High Very High
Potency 2 94.08 High High
Intracerebroventricular 1 91.48 High High
iatrogenic 1 91.20 High High
ketamine 1 88.64 High High
Peripheral nervous system 1 85.92 High High
Disease Link Frequency Relevance Heat
Peripheral Neuropathy 13 99.20 Very High Very High Very High
Disease 79 98.96 Very High Very High Very High
Chronic Renal Failure 29 97.72 Very High Very High Very High
Headache 18 97.36 Very High Very High Very High
Targeted Disruption 4 94.24 High High
Diabetes Mellitus 22 92.28 High High
Cancer 7 91.24 High High
Convulsion 3 90.64 High High
Recurrence 105 89.00 High High
Malaria 210 87.40 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that IV GCRP causes dilation of the MMA but not the MCA in healthy volunteers, and that sumatriptan reverses the dilation of the MMA caused by CGRP.


Gene_expression (dilation) of MMA in MMA
1) Confidence 0.44 Published 2010 Journal Neurology Section Body Doc Link 20975053 Disease Relevance 0.11 Pain Relevance 0
RESULTS: Compared with placebo, CGRP caused significant dilation of MMA (p = 0.006) and no dilation of MCA (p = 0.69).
Gene_expression (dilation) of MMA in MCA
2) Confidence 0.44 Published 2010 Journal Neurology Section Body Doc Link 20975053 Disease Relevance 0.16 Pain Relevance 0
Association between asymptomatic carriage and MMA occurrence
Gene_expression (occurrence) of MMA in MMA
3) Confidence 0.31 Published 2008 Journal Malar J Section Body Doc Link PMC2567330 Disease Relevance 0.09 Pain Relevance 0
Children could present a MMA at the end of the transmission season, with no noticeable benefit due to IPT.
Neg (no) Gene_expression (present) of MMA in MMA
4) Confidence 0.31 Published 2008 Journal Malar J Section Body Doc Link PMC2567330 Disease Relevance 0.14 Pain Relevance 0
The results of the present study show the absence of effect of age on children susceptibility to present a MMA, which is an important individual parameter concerning the acquisition of immunity.
Gene_expression (present) of MMA in MMA
5) Confidence 0.31 Published 2008 Journal Malar J Section Body Doc Link PMC2567330 Disease Relevance 0.48 Pain Relevance 0
At the end of the transmission season, the frequency of asymptomatic carriers was similar to that observed at the beginning of the season (31.9%, p = 0.15), but no MMA was detected during this period.


Gene_expression (detected) of MMA in MMA
6) Confidence 0.27 Published 2008 Journal Malar J Section Abstract Doc Link PMC2567330 Disease Relevance 0.41 Pain Relevance 0
Subjects who presented no MMA during the follow-up were censored at the endpoint, at Day 9.
Neg (no) Gene_expression (presented) of MMA in MMA
7) Confidence 0.27 Published 2008 Journal Malar J Section Body Doc Link PMC2567330 Disease Relevance 0 Pain Relevance 0
The Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003 guaranteed a drug benefit in the form of prescription drug plans (PDPs) available to all program beneficiaries as of January 1, 2006.1 The legislation addressed a major problem in the pre-MMA era, namely that 9 out of 10 Medicare beneficiaries take prescription medications but more than one-quarter had no coverage to help them afford the costs of their medications, as well as those of necessities such as food or heat.2–6
Gene_expression (era) of MMA in MMA
8) Confidence 0.16 Published 2007 Journal J Gen Intern Med Section Body Doc Link PMC1824717 Disease Relevance 0 Pain Relevance 0
The Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003 guaranteed a drug benefit in the form of prescription drug plans (PDPs) available to all program beneficiaries as of January 1, 2006.1 The legislation addressed a major problem in the pre-MMA era, namely that 9 out of 10 Medicare beneficiaries take prescription medications but more than one-quarter had no coverage to help them afford the costs of their medications, as well as those of necessities such as food or heat.2–6
Gene_expression (era) of MMA in MMA
9) Confidence 0.16 Published 2007 Journal J Gen Intern Med Section Body Doc Link PMC1824717 Disease Relevance 0 Pain Relevance 0
We studied the mRNA expression profile of K(ATP) channel subunits in the pig and human middle meningeal artery (MMA) and in the pig middle cerebral artery (MCA).
Gene_expression (expression) of MMA in MCA
10) Confidence 0.15 Published 2008 Journal Eur. J. Pharmacol. Section Abstract Doc Link 18996111 Disease Relevance 0.24 Pain Relevance 0.24
However, systemic production of MMA persists after kidney Tx, despite dietary protein restriction, so that plasma MMA remains at a lower range than before Tx according to post-Tx GFR but still many times greater than that in healthy subjects [62].
Gene_expression (production) of MMA in plasma
11) Confidence 0.04 Published 2009 Journal Pediatr Nephrol Section Body Doc Link PMC2753770 Disease Relevance 1.18 Pain Relevance 0.04
Visual analysis of electroencephalographic recordings (EEG) showed that MMA injection induced the appearance of high-voltage synchronic spike activity in the ipsilateral cortex which spreads to the contralateral cortex while quantitative electroencephalographic analysis showed larger wave amplitude during MMA-induced seizures in wild-type mice when compared with iNOS knockout mice.
Gene_expression (injection) of MMA in cortex associated with targeted disruption and convulsion
12) Confidence 0.04 Published 2009 Journal Int. J. Dev. Neurosci. Section Abstract Doc Link 19073247 Disease Relevance 0.65 Pain Relevance 0.12
We recently identified carboxypeptidase M (CPM) as a macrophage maturation-associated antigen detected by mAb MAX. 1/MAX. 11.
Gene_expression (detected) of maturation-associated in macrophage
13) Confidence 0.02 Published 2000 Journal Adv. Exp. Med. Biol. Section Abstract Doc Link 10849748 Disease Relevance 0.27 Pain Relevance 0.17
Cbl therapy led to improvements in Hcy and MMA levels in all groups, and PN in PD-IPN patients stabilized during therapy.
Gene_expression (levels) of MMA in MMA associated with ipn, peripheral neuropathy and disease
14) Confidence 0.01 Published 2008 Journal Mov. Disord. Section Abstract Doc Link 18785232 Disease Relevance 2.32 Pain Relevance 1.20
For oral As dosage, solutions of MMA, DMA, AsIII, or AsV (80–100 ?
Gene_expression (solutions) of MMA in MMA
15) Confidence 0.01 Published 2006 Journal Environ Health Perspect Section Body Doc Link PMC1764129 Disease Relevance 0 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox